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Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and
SLC22A2 In Vitro
Darren M. Moss, Neill J. Liptrott, Paul Curley, Marco Siccardi, David J. Back, Andrew Owen
Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
Rilpivirine is a nonnucleoside reverse transcriptase inhibitor approved for treatment of HIV-1 infection in antiretroviral-naive
adult patients. Potential interactions with drug transporters have not been fully investigated. Transport by and inhibition of
drug transporters by rilpivirine were analyzed to further understand the mechanisms governing rilpivirine exposure and deter-
mine the potential for transporter-mediated drug-drug interactions. The ability of rilpivirine to inhibit or be transported by
ABCB1 was determined using ABCB1-overexpressing CEMVBL100 cells and Caco-2 cell monolayers. The Xenopus laevis oocyte
heterologous protein expression system was used to clarify if rilpivirine was either transported by or inhibited the function of
influx transporters SLCO1A2, SLCO1B1, SLCO1B3, SLC22A2, SLC22A6, and SLC22A8. The ability of rilpivirine to inhibit or be
transported by SLC22A1 was determined using SLC22A1-expressing KCL22 cells. Rilpivirine showed higher accumulation in
SLC22A1-overexpressing KCL22 cells than control cells (27% increase, P 0.03) and inhibited the functionality of SLC22A1 and
SLC22A2 transport with 50% inhibitory concentrations (IC50s) of 28.5Mand 5.13M, respectively. Inhibition of ABCB1-me-
diated digoxin transport was determined for rilpivirine, which inhibited digoxin transport in the B-to-A direction with an IC50
of 4.48M. Themaximum rilpivirine concentration in plasma in patients following a standard 25-mg dosing regimen is around
0.43M, lower than that necessary to substantially inhibit ABCB1, SLC22A1, or SLC22A2 in vitro. However, these data indicate
that SLC22A1may contribute to variability in rilpivirine exposure and that interactions of rilpivirine with substrates of
SLC22A1, SLC22A2, or ABCB1may be possible.
Rilpivirine is a nonnucleoside reverse transcriptase inhibitorwhich has been approved for use in treatment-naive adult
HIV-infected patients. The drug shows high potency, with an in
vitro 50% effective concentration of 0.73 nM against HIV, and is
associated with fewer neuropsychiatric side effects than efavirenz
(1, 2).
The absorption of rilpivirine is affected by gastric pH.Omepra-
zole and famotidine reduced the rilpivirine maximum concentra-
tion (Cmax) by 40% and 85%, respectively, although intake of fa-
motidine 12 h prior to rilpivirine did not affect rilpivirine
absorption (3). Food also influences rilpivirine absorption, with
an40% increase in drug exposure seen when rilpivirine is taken
with a normal or high-caloriemeal comparedwith that seen under
fasted conditions. Rilpivirine is metabolized primarily by cyto-
chrome P450 3A (CYP3A), and drugs which inhibit or induce
CYP3A may alter rilpivirine exposure in patients (4). Rilpivirine
inhibits CYP3A4, CYP2B6, and CYP2C19 in vitro, although the
ability of the drug to inhibit these enzymes in vivo is not fully
known (5).
A recent phase III, randomized trial in treatment-naive HIV-
1-infected adults (ECHO) demonstrated that rilpivirine was non-
inferior (efficacy) to efavirenz and had an improved safety profile
compared with that of efavirenz (2). However, rilpivirine did
show a higher virological failure rate than efavirenz (13% versus
6%), which was also observed in a parallel phase III trial
(THRIVE) (6). The causes of this higher incidence of the virolog-
ical failure rate are not fully understood, although the possibility
of inadequate penetration of drug into tissues or infected cellsmay
be a factor. Drug transporter proteins are involved in the move-
ment of many drugs between blood and tissues and may be a
factor in the disposition of several antiretrovirals (7), and an in-
creased understanding of the role of transporters in rilpivirine
disposition may help explain the observed virological failure.
The impact of drug transporters on rilpivirine disposition has
not been fully investigated. In a previous study, growth inhibition
assays in MDCKII cells overexpressing human ABCB1, ABCG2,
ABCC1, and ABCC2 were used as a surrogate for the substrate
characteristics of rilpivirine, although direct concentration mea-
surements of rilpivirine or control substrates were not determined
(5). An increased knowledge of the mechanisms that control the
rilpivirine disposition may help rationalize or even anticipate
drug-drug interactions (2, 6) and will identify candidate trans-
porter genes for future pharmacogenetic studies. Of particular
note, rilpivirine is known to increase the serum levels of creati-
nine, suggesting the possible inhibition of kidney-expressed cat-
ion transporters (2, 8). The aim of this study was to investigate the
transport of rilpivirine by the efflux transporter ABCB1 (P glyco-
protein) at both physiological and superphysiological levels and
to investigate the potential transport of rilpivirine by major hu-
man drug influx transporters (7). Influx transporters character-
ized were the liver-expressed SLCO1B1 (OATPC), SLCO1B3
(OATP8), and SLC22A1 (OCT1), the kidney-expressed SLC22A2
(OCT2), SLC22A6 (OAT1), and SLC22A8 (OAT3), and the brain-
expressed SLCO1A2 (OATPA) (9). Inhibition of ABCB1 and in-
flux transporters by rilpivirine was also determined. All transport-
ers tested, apart from SLCO1A2 and SLCO1B3, have been
associated with clinical drug-drug interactions, and transporters
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were selected using FDA and International Transporter Consor-
tium guidelines (10, 11).
MATERIALS AND METHODS
Materials. CEM and CEMVBL100 cells were donated by Ross Davey, Bill
Walsh Cancer Research Laboratories (St. Leonards, Australia). Caco-2
cells were purchased from the EuropeanCollection ofCell Cultures (Salis-
bury, United Kingdom). SLC22A1-overexpressing KCL22 cells and
mock-transfected KCL22 cells were donated by Athina Giannoudis, De-
partment of Hematology, Royal Liverpool University Hospital (Liver-
pool, United Kingdom). [14C]rilpivirine (specific activity  20.00 mCi/
mmol) and nonradiolabeled rilpivirine were gifts from Tibotec
(Mechelen, Belgium). [3H]estrone-3-sulfate (specific activity  50 Ci/
mmol), [14C]tetraethyl ammonium (specific activity  55 mCi/mmol),
[3H]aminohippuric acid (specific activity 5 Ci/mmol), and [14C]man-
nitol (specific activity 55 mCi/mmol) were purchased from American
Radiolabeled Chemicals (MO). [3H]digoxin (specific activity  50 Ci/
mmol) and [14C]metformin (specific activity 0.1 Ci/mmol) were pur-
chased fromPerkinElmer (Boston,MA). [3H]lopinavir (specific activity 5
Ci/mmol) was purchased from Moravek Biochemicals (CA). Lopinavir
was a gift from Abbott (IL). Tariquidar (XR9576) was purchased from
Xenova (Sloane, United Kingdom). cDNA clones were purchased from
Source BioScience United Kingdom (Nottingham, United Kingdom).
mMessage transcription kits were purchased from Ambion Ltd. (Hunt-
ingdon, United Kingdom). Ultima Gold scintillation fluid was purchased
from PerkinElmer (Boston, MA). Restriction enzymes were purchased
from New England BioLabs (Hitchen, United Kingdom). Adult female
Xenopus laevis frogs were purchased from Xenopus Express (Lyon,
France). All other drugs and reagents were obtained from Sigma (Poole,
United Kingdom).
Accumulation experiments using CEM and CEMVBL100 cells. CEM
and CEMVBL100 cells were maintained in cell culture medium (RPMI,
10% [vol/vol] fetal calf serum [FCS]) prior to the experiment (37°C, 5%
CO2). CEM cells are a wild-type T-lymphoblastoid cell line. CEMVBL100
cells are CEM cells which have greatly increased ABCB1 expression (se-
lected using vinblastine up to a concentration of 100 ng/ml). On the day of
the experiment, CEMandCEMVBL100 cells of a constant cell density (1ml,
5 106 cells/ml)were incubated (37°C, 5%CO2) for 30min in cell culture
medium (RPMI, 10% [vol/vol] FCS) containing either rilpivirine (20
M) or a control ABCB1 substrate, lopinavir (1 M). A separate incuba-
tion was undertaken where CEMVBL100 cells were preincubated prior to
the substrate addition in cell culture medium containing the potent non-
competitive ABCB1 inhibitor tariquidar (RPMI, 10% [vol/vol] FCS, 300
nM tariquidar, 30 min). Tariquidar was also included during the 30-min
substrate incubation. Following incubation, cells were centrifuged (800
g, 1°C, 1min) and supernatant fractionswere taken for analysis. Cells were
washed three times using ice-cold Hanks balanced salt solution (HBSS),
centrifuged (800  g, 1°C, 1 min), and lysed with the addition of 100 l
tap water. Cells were vortexed for 5 min, and samples were added to
scintillation vials. Four milliliters of scintillation fluid was added to the
scintillation vials, which were then loaded into a liquid scintillation ana-
lyzer (Beckman Tri-Carb). Intracellular drug concentrations were deter-
mined, assuming a volume of 1 pl per cell (12).
Bidirectional transport experiments using Caco-2 cell monolayers.
Caco-2 cells were maintained in cell culture (37°C, 5%CO2) by passaging
at 70% confluence using cell culture medium (Dulbecco’s modified Eagle
medium [DMEM], 15% [vol/vol] FCS). The passage number of the cells
used in this study was between 25 and 30. Caco-2 cell monolayers were
cultured, and transwell monolayers were created as previously described
(13). Briefly, confluent Caco-2 cells were seeded onto polycarbonate
membrane transwells at a density of 5 105 cells/cm2. Medium was ini-
tially replaced after 24 h andwas then replaced every 48 h. Plates were used
in the experiments at 21 days after seeding. Monolayer integrity was
checked on the day of the experiment using a Millicell ERS system (Mil-
lipore) to determine the transepithelial electrical resistance (TEER) across
the monolayer. A TEER of 600  was deemed acceptable. In addition,
radiolabeled [14C]mannitol was added to each well to confirmmonolayer
integrity.Mannitol samples were analyzed by liquid scintillation counting
(BeckmanTri-Carb), andwells were used for experimental analysis only if
the apparent permeation of mannitol was less than 1 cm 106 s1.
The movement of rilpivirine across Caco-2 cell monolayers and the
impact of an ABCB1 inhibitor on this movement were assessed. The
monolayer TEER was determined, the medium in each well was replaced
with warm transport buffer (HBSS, 25mMHEPES, 0.1% [wt/vol] bovine
serumalbumin, pH7), and the cells and buffer were allowed to equilibrate
(37°C, 30 min). For inhibition studies, this transport buffer contained
tariquidar (300 nM). The transport buffer in the apical (for transport in
the A-to-B direction) and basolateral (for transport in the B-to-A direc-
tion) chambers was replaced with transport buffer containing rilpivirine
(20 M) with or without 300 nM tariquidar. Samples (50 l) were taken
from the receiver compartment at 0, 30, and 60 min and replaced with an
equal volume of transport buffer. Samples were analyzed using a liquid
scintillation counter (Beckman Tri-Carb). Data were used to determine
the rilpivirine apparent permeation (Papp; cm s
1) for each direction and
the efflux ratio (ratio of the Papp in the B-to-A direction to the Papp in the
A-to-B direction). Papp was calculated using the following equation, as
described previously:Papp (10
6) [(dQ/dt)V]/(AC0), where dQ/dt
is the change in drug concentration in the receiver chamber over time (nM
s1), V is the volume in the receiver compartment (ml), A is the total
surface area of the transwell membrane (cm2), C0 is the initial drug con-
centration in the donor compartment (nM), and Papp is the apparent
permeation (106 cm s1) (14).
In addition, the above-described experiment was repeated using
digoxin (1 M) as a control ABCB1 substrate and assessing the impact of
rilpivirine (1, 3, 10, and 30 M) and tariquidar (300 nM) on the digoxin
Papp in both directions.
Production of uptake transporter cRNA for Xenopus laevis oocyte
injection. SLCO1A2, SLCO1B1, and SLCO1B3 were cloned from cDNA
extracted from Huh-7D12 and A549 cells as described previously (15).
IMAGE clones of SLC22A2, SLC22A6, and SLC22A8 were purchased
from Source Bioscience United Kingdom (Nottingham, United King-
dom). Transporter gene-containing plasmids from clones were extracted,
linearized, and used as a template in cRNA production using a mMessage
mMachine RNA transcription kit (Ambion) following themanufacturer’s
protocol.
Xenopus laevis oocyte isolation, collagenase treatment, and micro-
injection. Oocytes were harvested from sacrificed adult female Xenopus
laevis frogs and treated with modified Barth’s solution not containing
calcium (88 mM NaCl, 1 mM KCl, 15 mMHEPES, 100 U penicillin, 100
g streptomycin, pH 7.4) but containing collagenase (1 mg/ml, 22°C, 60
rpm, 1 h). Cells were transferred to Barth’s solution containing calcium
(88 mM NaCl, 1 mM KCl, 15 mM HEPES, 0.3 mM CaCNO3·6H2O, 41
MCaCl2·6H2O, 0.82 mMMgSO4·7H2O, 100 U penicillin, 100g strep-
tomycin, pH 7.4) and stored in a cold room at 8°C. Healthy cells were
selected and injected with transporter cRNA (50 ng per oocyte, 1 ng/nl) or
sterile water (50 nl) and maintained in Barth’s solution containing cal-
cium to allow transporter expression (5 days for SLCO1B3-injected
oocytes, 3 days for all other conditions, 18°C). Barth’s solution was re-
placed daily, and damaged oocytes were removed.
Drug accumulation in transporter RNA-injected Xenopus laevis
oocytes. Drug accumulation studies using X. laevis oocytes were per-
formed as described previously with slight modifications (15). For exper-
iments determining rilpivirine transport, radiolabeled rilpivirine was in-
cubated in Hanks balanced salt solution (pH 7.4) with at least 6 oocytes
per condition in a 48-well Nunc flat-bottom plate (500 l, 20 M, room
temperature, shaking at 60 rpm, 1 h). Radiolabeled positive-control drugs
were tested alongside rilpivirine to confirm successful transporter expres-
sion. The positive-control drugs used were estrone-3-sulfate (1 M) for
SLCO1A2, SLCO1B1, and SLCO1B3, aminohippuric acid (1 M) for
SLC22A6, andmetformin (2M) for SLC22A2. Inhibition of drug trans-
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porters by rilpivirine was initially assessed by coincubating positive-con-
trol substrates with 10 M rilpivirine. SLC22A2-mediated metformin
transport was reduced in the presence of rilpivirine; therefore, a 50%
inhibitory concentration (IC50) curve was determined using 1, 2.5, 5, 10,
25, 50, and 100 M rilpivirine. All incubations were terminated by trans-
ferring oocytes to cell strainers and washing in ice-cold HBSS to remove
extracellular drug. Each oocyte was placed in a separate scintillation vial, fol-
lowed by addition of 100l 10% SDS. After disintegration of the oocytes by
the SDS, 4ml scintillationfluidwas added to all vials, whichwere then loaded
into a liquid scintillation analyzer (BeckmanTri-Carb). Results are expressed
as the concentration (M) of drug in oocytes  standard deviation (SD),
assuming that each oocyte had a volume of 1l (15).
Creation and culture ofmock-transfected and SLC22A1-expressing
KCL22 cells.KCL22 cells weremaintained in cell culturemedium (RPMI,
10% [vol/vol] FCS) prior to the experiment in a CO2 incubator (37°C, 5%
CO2). SLC22A1-expressing KCL22 cells and mock-transfected KCL22
cells were created previously by Athina Giannoudis at the Department of
Hematology, Royal Liverpool University Hospital, Liverpool, United
Kingdom (16). In the previous work, SLC22A1-overexpressing KCL22
cells were created by transfecting plasmid pcDNA-hSLC22A1 into cells by
nucleofection. Similarly, mock-transfected KCL22 cells were created by
transfecting the empty vector pcDNA3.1 into cells by nucleofection.
Transfected cells were selected using neomycin, and stable cell lines were
established. KCL22 cells were used for human SLC22A1 transfection be-
cause it expresses a small basal amount of SLC22A1 in comparison to
other chronic myelogenous leukemia cell lines (17).
Rilpivirine accumulation and inhibitory potential in SLC22A1-
overexpressing KCL22 cells.On the day of the experiment, mock-trans-
fected KCL22 cells and SLC22A1-expressing KCL22 cells of a constant cell
density (1 ml, 2.5 106 cells/ml) were incubated (37°C, 5% CO2) for 30
min in cell culture medium (RPMI, 10% [vol/vol] FCS) containing either
rilpivirine (20 M) or the control SLC22A1 substrate tetraethyl ammo-
nium (1 M). A separate incubation was undertaken, where SLC22A1-
expressing KCL22 cells were preincubated prior to the substrate addition
in cell culturemedium containing the potent SLC22A1 inhibitor prazosin
(RPMI, 10% [vol/vol] FCS, 100 M prazosin, 30 min). Prazosin was also
included during the 30-min substrate incubation. Following incubation,
cells were centrifuged (800 g, 1°C, 1 min) and processed for analysis as
described for CEM cells. Using intracellular radioactivity readings, cellu-
lar drug concentrations (M)  SD were determined in each cell line,
assuming a 1-pl volume per cell.
The inhibitory potential of rilpivirine for SLC22A1 transport was as-
sessed. Accumulation of tetraethyl ammonium (5.5M) was determined
when cells were coincubated with a log range of rilpivirine concentrations
(0, 1, 2.5, 5, 10, 25, 50, 100 M). A parallel experiment was performed
using prazosin as a positive-control SLC22A1 inhibitor. Data were plotted
using Prism (version 5) software, and slopes were used to calculate the
relative IC50 (the amount of drug needed to achieve 50% SLC22A1 inhi-
bition, as determined from the maximum and minimum extremes of the
nonlinear regression plot).
Statistical analysis.DatawereanalyzedusingSPSS(version19) forWin-
dows. IC50 curves were generated using Prism (version 5) for Windows. All
data were tested for normality using the Shapiro-Wilk test. An independent t
test was used to determine the significance of normally distributed data, and
theMann-Whitney U test was used for all other data. A two-tailed P value of
	0.05 was accepted as being statistically significant.
RESULTS
Rilpivirine accumulation inwild-type andABCB1-overexpress-
ing CEM cells. Cellular accumulation of rilpivirine was determined
in CEM and ABCB1-overexpressing CEMVBL100 cells, and the effect
of the ABCB1 inhibitor tariquidar on this accumulation was investi-
gated (Fig. 1A). Rilpivirine accumulation inCEMVBL100 cells (54.1
1.6 M) was not significantly different from that in CEM cells
(48.7 1.9 M, P 0.11). Tariquidar treatment did not alter rilpi-
virine accumulation in CEMVBL100 cells (P  0.23). The control
ABCB1 substrate lopinavir had lower accumulation in CEMVBL100
cells (10.3 0.9 M) than in CEM cells (17.9 1.5 M, P	 0.01)
(Fig. 1B). This difference in lopinavir accumulation between CEM
andCEMVBL100 cellswas lostwhenCEMVBL100 cellswere treatedwith
tariquidar (19.8 0.7M, P 0.10).
Impact of tariquidar on rilpivirine Caco-2 cell monolayer
permeation. The Papp values obtained for rilpivirine with and
without tariquidar are given in Fig. 1C. All Papp values and efflux
ratio calculations were made using the samples taken after 60 min
of incubation as sink conditions were maintained. Rilpivirine
showed significantly higher transport in the B-to-A direction
(Papp  6.6  10
6  0.6  106 cm s1) than in the A-to-B
direction (Papp 4.0 10
6 0.7 106 cm s1, P	 0.01). The
efflux ratio (Papp in the B-to-A direction/Papp in the A-to-B direc-
tion) of rilpivirine at 60 min was 1.65. When incubations were
repeated in the presence of the ABCB1 inhibitor tariquidar, no
significant alteration in rilpivirine permeation was determined in
either the A-to-B direction (Papp 3.9 10
6 0.7 106 cm
s1, P 0.88) or the B-to-A direction (Papp 6.6 10
6 0.9
106 cm s1, P 0.93).
Impact of rilpivirine on digoxin Caco-2 cell monolayer perme-
ation.The ability of rilpivirine to inhibit ABCB1-mediated transport
of digoxin was assessed using Caco-2 cell monolayers (Fig. 1D). Per-
meation of 1 M digoxin in the A-to-B direction was significantly
increased when it was coincubated with rilpivirine at 1 M (Papp
2.1 106  0.3 106 cm s1, P 0.01), 3 M (Papp  4.2
106 1.6 106 cm s1,P 0.04), 10M(Papp 10.9 10
6
2.5 106 cm s1, P	 0.01), and 30 M (Papp 12.1 10
6
0.2  106 cm s1, P 	 0.01) compared with that for the rilpi-
virine-free controls (Papp 1.3 10
6 0.1 106 cm s1).
Permeation of 1 M digoxin in the B-to-A direction was sig-
nificantly decreasedwhen itwas coincubatedwith 10Mrilpivirine
[Papp (22.2 6.0) 10
6 cm s1,P 0.02] and 30Mrilpivirine
[Papp  (18.2  2.7)  10
6 cm s1, P  0.01], compared with
rilpivirine-free control incubations [Papp (64.2 8.6) 10
6 cm
s1]. Rilpivirine reducedpermeation in theA-to-Bdirection, perme-
ation in the B-to-A direction, and the efflux ratio of digoxin with
IC50s of 4.24 M (95% confidence interval [CI], 2.94 to 6.10 M),
4.48 M (95% CI, 2.52 to 7.96 M), and 1.08 M (95% CI, 0.67 to
1.73 M), respectively. The control ABCB1 inhibitor tariquidar in-
creased the permeation of digoxin in the A-to-B direction (Papp 
16.6  106  3.4  106 cm s1, P  0.02) and decreased the
permeationofdigoxin in theB-to-Adirection (Papp14.710
6
3.6 106 cm s1,P	 0.01), resulting in a digoxin efflux ratio of 0.9
(Fig. 1D).
Rilpivirine accumulation and inhibitory potential in trans-
porter cRNA-injectedXenopus laevisoocytes.The accumulation
of rilpivirine was determined in SLCO1A2, SLCO1B1, SLCO1B3,
SLC22A2, SLC22A6, and SLC22A8 cRNA-injected X. laevis
oocytes. Water-injected oocytes were also used in accumulation
experiments to determine passive diffusion of the drug into
oocytes, and control substrates were used to validate functional
transporter expression. The control substrates used were estrone-
3-sulfate (SLC22A8, SLCO1A2, SLCO1B1, SLCO1B3), aminohip-
puric acid (SLC22A6), and metformin (SLC22A2). The ability of
rilpivirine to inhibit accumulation of control substrates was also
assessed. The amount of drug accumulation in transporter cRNA-
injected oocytes compared to that in water-injected control
oocytes was determined and is given in Fig. 2.
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Rilpivirine accumulation was not altered in oocytes expressing
SLC22A2 (68.55 12.22 M, P 0.14), SLC22A6 (54.80 5.44
M, P 0.09), SLC22A8 (62.67 5.91M, P 0.72), SLCO1A2
(66.50 6.93 M, P 0.65), SLCO1B1 (67.72 15.16 M, P
0.38), or SLCO1B3 (73.27 10.03 M, P 0.41) in comparison
to that in water-injected control oocytes (60.31 2.81 M) (Fig.
2A). Estrone-3-sulfate accumulation was higher in oocytes express-
ing SLC22A8 (0.62 0.10 M, P 0.002), SLCO1A2 (3.63 0.52
M, P 	 0.001), SLCO1B1 (5.95  0.62 M, P 	 0.001), and
SLCO1B3 (0.45  0.04 M, P  0.009) than in water-injected
control oocytes (0.24 0.05 M). Aminohippuric acid accumu-
lation was higher in oocytes expressing SLC22A6 (6.07  0.54
M, P  0.002) than in water-injected control oocytes (0.22 
0.01 M). Metformin accumulation was higher in oocytes ex-
pressing SLC22A2 (1.36  0.16 M, P 	 0.001) than in water-
injected control oocytes (0.23  0.06 M). Rilpivirine at 10 M
did not alter the accumulation of estrone-3-sulfate in oocytes
expressing SLC22A8 (P 0.92), SLCO1A2 (P 0.83), SLCO1B1
(P 0.38), or SLCO1B3 (P 0.53) (Fig. 2B) and also did not alter
the accumulation of aminohippuric acid in oocytes expressing
SLC22A6 (P  0.64) (Fig. 2C). Accumulation of metformin in
oocytes expressing SLC22A2 was reduced in the presence of rilpi-
virine; therefore, the IC50s determined for rilpivirine and the con-
trol SLC22A2 inhibitor quinidine were 5.13 M and 40.45 M,
respectively (Fig. 2D).
Rilpivirine accumulation and inhibitory potential in
SLC22A1-expressing KCL22 cells. The accumulation of rilpi-
virine in transfected SLC22A1-expressing KCL22 cells and mock-
transfected KCL22 cells was determined and compared to the ril-
pivirine accumulation in cells coincubated with the SLC22A1
inhibitor prazosin. Accumulation of the control SLC22A1 sub-
strate tetraethyl ammonium was also determined.
Rilpivirine showed a small but statistically significantly higher
accumulation in SLC22A1-expressing KCL22 cells (88.8  5.9
M, P  0.031) than in mock-transfected cells (70.0  8.0 M)
(Fig. 3B). The control inhibitor prazosin caused a small but sig-
nificant decrease in rilpivirine cellular accumulation in SLC22A1-
expressing cells (14% reduction, P  0.04). Tetraethyl ammo-
nium showed higher accumulation in SLC22A1-expressing
KCL22 cells (1.6 0.02 M, P	 0.01) than in mock-transfected
cells (0.12  0.01 M) (Fig. 3A). Prazosin decreased tetraethyl
ammonium cellular accumulation in SLC22A1-expressing cells
(77% reduction, P	 0.01). The inhibition of SLC22A1 was deter-
mined using a concentration range of rilpivirine and prazosin and
used to calculate IC50s (Fig. 3C). Rilpivirine inhibited tetraethyl
ammonium accumulation in SLC22A1-overexpressing cells with
a relative IC50 of 28.5 M. Prazosin (100 M) achieved an 84%
reduction in cellular tetraethyl ammonium accumulation and a
relative IC50 of 2.3 M, which are similar to data in the literature
(18).
DISCUSSION
Drug interactions involving antiretroviral drugs can potentially
lead to therapy failure and/or exacerbate adverse drug reactions.
In this study, we have investigated the interactions of rilpivirine
FIG 1 (A) Rilpivirine (RPV) accumulation in CEM, CEMVBL100 (VBL), and CEMVBL100 cells treated with 300 nM tariquidar. Data are expressed as mean the
rilpivirine concentration in cells (M; n 3 experimental replicates) SD. (B) Lopinavir (LPV) accumulation inCEM,CEMVBL100, andCEMVBL100 cells treated
with 300 nM tariquidar (TAR). Data are expressed as the mean lopinavir concentration in cells (M; n 3 experimental replicates) SD. (C) Permeation of
rilpivirine in the A-to-B (black bars) and B-to-A (gray bars) directions across a Caco-2 cell monolayer with and without the presence of 300 nM tariquidar. Data
are expressed as themean Papp (10
6 cm s1; n 3 experimental replicates) SD. (D) Permeation of digoxin (DGX) in the A-to-B (black bars) and B-to-A (gray
bars) directions across a Caco-2 cell monolayer with and without the presence of a range of rilpivirine concentrations or 300 nM tariquidar. Data are expressed
as the mean Papp (10
6 cm1; n 3 experimental replicates) SD. *, P	 0.05; **, P 0.01.
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with a selection of key drug transporters to improve our under-
standing of the factors involved in rilpivirine pharmacokinetics.
The results from accumulation and bidirectional monolayer
permeation experiments confirm that rilpivirine is not trans-
ported by ABCB1. The extent of rilpivirine transport by ABCB1
was not significant compared to the transport of the positive con-
trols lopinavir and the cardiac glycoside digoxin. Indeed, the FDA
guidelines recommend that a drug should achieve an efflux ratio
of at least 2 in Caco-2 cell monolayers and show a greater than
50% reduction in efflux ratio when an ABCB1 inhibitor is used, in
order for ABCB1 transport to be considered relevant in vivo (19).
In our Caco-2 cell experiment, rilpivirine achieved an efflux ratio
of only 1.65, with no alteration observedwhen tariquidarwas used
to inhibit ABCB1. The small efflux ratio obtained for rilpivirine
suggests that active efflux in the gut is unlikely to be important in
vivo. Therefore, no other intestinal efflux transporters were as-
sessed in this study.
Rilpivirine inhibited ABCB1-mediated transport of digoxin
through Caco-2 cell monolayers. This suggests that rilpivirine
may influence the movement of ABCB1 substrates across cell
membrane barriers which are high in ABCB1 expression, such as
themucosal surface epithelial cells in the intestine, the biliary can-
alicular surface of hepatocytes in the liver, the brush bordermem-
brane of renal proximal tubular cells in the kidney, and the blood-
brain barrier (8, 20–22). However, rilpivirine did not alter the
exposure of the ABCB1 substrate digoxin in healthy volunteers,
which suggests that the observed in vitro inhibition of ABCB1 by
rilpivirine is not clinically relevant (4).
In oocyte accumulation studies, rilpivirine was not a substrate
of any transporter tested but did inhibit SLC22A2-mediated
transport of the antidiabetic drug metformin with an IC50 of 5.13
M. Therefore, there is the potential for an interaction between
rilpivirine and other SLC22A2 substrates, although this will de-
pend on the concentration of inhibitor [I] and the IC50 (i.e., [I]/
IC50). Given that the rilpivirine concentration (Cmax 0.43 M)
(3) is less than the IC50, it seems unlikely that this will be a mech-
anism of clinically relevant interactions or would fully explain the
small increase in creatinine levels in patients taking rilpivirine (8).
This is in contrast to the findings for dolutegravir, as the drug
causes notable inhibition of SLC22A2 in vitro (IC50 1.9 M) at
a concentration which is about 4-fold lower than the Cmax ([I]/
IC50 4.2) (23). This inhibition is consistent with the 10 to 14%
increase in serum creatinine observed in patients taking dolute-
gravir (24). A recent publication by Weiss et al. used transfected
HEK293 cells to show that rilpivirine was a weak inhibitor of
SLCO1B1 and SLCO1B3 only at superphysiological concentra-
tions (5). Furthermore, there have been no clinical interactions
reported which would suggest that rilpivirine can alter the dispo-
sition of SLCO substrates; therefore, the potential for SLCO-me-
diated interactions is unlikely.
SLC22A1 is predominantly expressed in the liver and acts to
remove substrates from the blood and into hepatic cells. The nu-
FIG 2 (A) Accumulation of rilpivirine (RPV) in X. laevis oocytes expressing various drug transporters (1 h, room temperature). Data are expressed as the
rilpivirine oocyte concentration (M; n 6 experimental replicates) SD. (B) Accumulation of the control substrate estrone-3-sulfate (E3S) inX. laevis oocytes
expressing various drug transporters with and without the addition of 10M rilpivirine. Data are expressed as the mean estrone-3-sulfate oocyte concentration
(M; n 7 experimental replicates) SD. (C) Accumulation of control substrate aminohippuric acid (AHA) in X. laevis oocytes expressing SLC22A6 with and
without the addition of 10M rilpivirine. Data are expressed as the mean aminohippuric acid oocyte concentration (M; n 8 experimental replicates) SD.
(D) Inhibition of metformin (MET) accumulation in SLC22A2-expressing X. laevis oocytes using a concentration range of rilpivirine or the control SLC22A2
inhibitor quinidine. Data are expressed as the mean percentage of metformin accumulation compared to the level of accumulation in drug-free control oocytes
(n 6 experimental replicates) SE.
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cleoside reverse transcriptase inhibitors (NRTIs) lamivudine and
zalcitabine are substrates of SLC22A1, and several protease inhib-
itors inhibit SLC22A1-mediated transport of these NRTIs in vitro
(25, 26). In the accumulation studies using transfected KCL22
cells, rilpivirine inhibited SLC22A1-mediated transport of tetra-
ethyl ammonium, which suggests the potential for an interaction
between rilpivirine and other SLC22A1 substrates. However, it
should be noted that passive diffusion of rilpivirine predominated
in KCL22 cells and the level of transport by SLC22A1 was low in
comparison.
In summary, rilpivirine shows inhibition of ABCB1, SLC22A1,
and SLC22A2 in vitro. However, the data should be interpreted in
the context that the rilpivirine peak plasma concentration follow-
ing administration of the standard 25-mg dose is approximately
0.43 M and that plasma protein binding is 99.7% (3, 5). None-
theless, it is not possible to rule out the possibility of the involve-
ment of these transporters in rilpivirine-mediated drug-drug in-
teractions because of the difficulties in extrapolating from in vitro
data to in vivo phenotypes. Since different substrates have differ-
ent affinities for transporters and since this interaction is likely to
be competitive, the IC50may be different for other drug substrates.
Also, rilpivirine may concentrate in specific tissues, raising the
concentrations available for transporter inhibition.
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